Search

Your search keyword '"Musuraca, Gerardo"' showing total 566 results
Start Over Author "Musuraca, Gerardo"
566 results on '"Musuraca, Gerardo"'

1. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Published
2024
Full Text
View/download PDF

2. Correction to: Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

Author

Di Rorà, Andrea Ghelli Luserna, Ghetti, Martina, Ledda, Lorenzo, Ferrari, Anna, Bocconcelli, Matteo, Padella, Antonella, Napolitano, Roberta, Fontana, Maria Chiara, Liverani, Chiara, Imbrogno, Enrica, Bochicchio, Maria Teresa, Paganelli, Matteo, Robustelli, Valentina, Sanogo, Seydou, Cerchione, Claudio, Fumagalli, Monica, Rondoni, Michela, Imovilli, Annalisa, Musuraca, Gerardo, Martinelli, Giovanni, and Simonetti, Giorgia

Published
2024
Full Text
View/download PDF

3. Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial

Author

Clerico, Michele, Ferrero, Simone, Alessandria, Beatrice, Zaccaria, Gian Maria, Genuardi, Elisa, Ragaini, Simone, Tavarozzi, Rita, Cavallo, Federica, Hohaus, Stefan, Musuraca, Gerardo, Carella, Angelo Michele, Stelitano, Caterina, Tani, Monica, Gaidano, Gianluca, Olivieri, Jacopo, Usai, Sara Veronica, Galimberti, Sara, Re, Francesca, Mian, Michael, Castellino, Claudia, Pavone, Vincenzo, Evangelista, Andrea, Bruno, Benedetto, Cortelazzo, Sergio, Passera, Roberto, and Ladetto, Marco

Published
2024
Full Text
View/download PDF

4. Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial

Author

Pulsoni, Alessandro, Ferrero, Simone, Tosti, Maria Elena, Luminari, Stefano, Dondi, Alessandra, Cavallo, Federica, Merli, Francesco, Liberati, Anna Marina, Cenfra, Natalia, Renzi, Daniela, Zanni, Manuela, Boccomini, Carola, Ferreri, Andrés J M, Rattotti, Sara, Zilioli, Vittorio Ruggero, Bolis, Silvia Anna, Bernuzzi, Patrizia, Musuraca, Gerardo, Gaidano, Gianluca, Perrone, Tommasina, Stelitano, Caterina, Tucci, Alessandra, Corradini, Paolo, Bigliardi, Sara, Re, Francesca, Cencini, Emanuele, Mannarella, Clara, Mannina, Donato, Celli, Melania, Tani, Monica, Annechini, Giorgia, Assanto, Giovanni Manfredi, Grapulin, Lavinia, Guarini, Anna, Cavalli, Marzia, De Novi, Lucia Anna, Bomben, Riccardo, Ciabatti, Elena, Genuardi, Elisa, Drandi, Daniela, Della Starza, Irene, Arcaini, Luca, Ricardi, Umberto, Gattei, Valter, Galimberti, Sara, Ladetto, Marco, Foà, Robin, and Del Giudice, Ilaria

Published
2024
Full Text
View/download PDF

5. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells

Author

Ghelli Luserna Di Rorà, Andrea, Ghetti, Martina, Ledda, Lorenzo, Ferrari, Anna, Bocconcelli, Matteo, Padella, Antonella, Napolitano, Roberta, Fontana, Maria Chiara, Liverani, Chiara, Imbrogno, Enrica, Bochicchio, Maria Teresa, Paganelli, Matteo, Robustelli, Valentina, Sanogo, Seydou, Cerchione, Claudio, Fumagalli, Monica, Rondoni, Michela, Imovilli, Annalisa, Musuraca, Gerardo, Martinelli, Giovanni, and Simonetti, Giorgia

Published
2023
Full Text
View/download PDF

6. Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 study

Author

Gini, Guido, Tani, Monica, Tucci, Alessandra, Marcheselli, Luigi, Cesaretti, Marina, Bellei, Monica, Pascarella, Anna, Ballerini, Filippo, Petrini, Mauro, Merli, Francesco, Olivieri, Attilio, Lanza, Francesco, Annibali, Ombretta, Zilioli, Vittorio Ruggero, Liberati, Anna Marina, Tisi, Maria Chiara, Arcari, Annalisa, Marino, Dario, Musuraca, Gerardo, Pavone, Vincenzo, Fabbri, Alberto, Pozzi, Samantha, Mannina, Donato, Plenteda, Caterina, Celli, Melania, and Luminari, Stefano

Published
2023
Full Text
View/download PDF

7. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

Author

Chiappella, Annalisa, Dodero, Anna, Evangelista, Andrea, Re, Alessandro, Orsucci, Lorella, Usai, Sara Veronica, Castellino, Claudia, Stefoni, Vittorio, Pinto, Antonio, Zanni, Manuela, Ciancia, Rosanna, Ghiggi, Chiara, Rossi, Francesca Gaia, Arcari, Annalisa, Ilariucci, Fiorella, Zilioli, Vittorio Ruggero, Flenghi, Leonardo, Celli, Melania, Volpetti, Stefano, Benedetti, Fabio, Ballerini, Filippo, Musuraca, Gerardo, Bruna, Riccardo, Patti, Caterina, Leonardi, Francesco, Arcaini, Luca, Magagnoli, Massimo, Cavallo, Federica, Bermema, Anisa, Tucci, Alessandra, Boccomini, Carola, Ciccone, Giovannino, Carniti, Cristiana, Pileri, Stefano Aldo, and Corradini, Paolo

Published
2023
Full Text
View/download PDF

8. A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma

Author

Arcari, Annalisa, Rigacci, Lugi, Tucci, Alessandra, Puccini, Benedetta, Usai, Sara Veronica, Cavallo, Federica, Fabbri, Alberto, Balzarotti, Monica, Pelliccia, Sabrina, Luminari, Stefano, Pennese, Elsa, Zilioli, Vittorio Ruggero, Mahmoud, Abdurraouf Mokhtar, Musuraca, Gerardo, Marino, Dario, Sartori, Roberto, Botto, Barbara, Gini, Guido, Zanni, Manuela, Hohaus, Stefan, Tarantini, Giuseppe, Flenghi, Leonardo, Tani, Monica, Di Rocco, Alice, Merli, Michele, Vallisa, Daniele, Pagani, Chiara, Nassi, Luca, Dessì, Daniela, Ferrero, Simone, Cencini, Emanuele, Bernuzzi, Patrizia, Mammi, Caterina, Marcheselli, Luigi, Tabanelli, Valentina, Spina, Michele, and Merli, Francesco

Published
2023
Full Text
View/download PDF

10. IgM-secreting diffuse large B-cell lymphoma: results of a multicentre clinicopathological and molecular study

Author

Cox, M. Christina, Marcheselli, Luigi, Scafetta, Giorgia, Visco, Carlo, Hohaus, Stefan, Annibali, Ombretta, Musuraca, Gerardo, Fabbri, Alberto, Cantonetti, Maria, Pelliccia, Sabrina, Papotti, Robel, Petrucci, Luigi, Tani, Monica, Battistini, Roberta, Arcari, Annalisa, Luminari, Stefano, Lopez, Gianluca, Alma, Eleonora, Pupo, Livio, Carli, Giuseppe, Marchesi, Francesco, Re, Francesca, Scarpino, Stefania, D’amore, Emanuele S. G., Larocca, Luigi M., Bianchi, Antonella, Pepe, Giuseppina, Natalino, Fiammetta, Anticoli-Borza, Paola, Cenfra, Natalia, Andriani, Alessandro, Abruzzese, Elisabetta, Tesei, Cristiano, Leoncini, Lorenzo, Asioli, Silvia, Ruco, Luigi, and Di Napoli, Arianna

Published
2022
Full Text
View/download PDF

11. Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial.

Author

Cerchione, Claudio, primary, Nappi, Davide, additional, Marchesini, Matteo, additional, Cangini, Delia, additional, Ronconi, Sonia, additional, Ceccolini, Michela, additional, Prochowski Iamurri, Andrea, additional, Matteucci, Federica, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Rossi, Alice, additional

Published
2024
Full Text
View/download PDF

12. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma

Author

Ferrero, Simone, Grimaldi, Daniele, Genuardi, Elisa, Drandi, Daniela, Zaccaria, Gian Maria, Alessandria, Beatrice, Ghislieri, Marco, Ferrante, Martina, Evangelista, Andrea, Mantoan, Barbara, De Luca, Gabriele, Stefani, Piero Maria, Benedetti, Fabio, Casaroli, Ivana, Zanni, Manuela, Castellino, Claudia, Pavone, Vincenzo, Petrini, Mario, Re, Francesca, Hohaus, Stefan, Musuraca, Gerardo, Cascavilla, Nicola, Ghiggi, Chiara, Liberati, Anna Marina, Cortelazzo, Sergio, and Ladetto, Marco

Published
2022
Full Text
View/download PDF

13. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

14. Management of Patients Treated With Oral Anticoagulant Therapy Undergoing Percutaneous Coronary Intervention With Stent Implantation: The PERSEO Registry.

Author

Sciahbasi, Alessandro, De Rosa, Salvatore, Gargiulo, Giuseppe, Giacoppo, Daniele, Calabrò, Paolo, Talarico, Giovanni Paolo, Zilio, Filippo, Talanas, Giuseppe, Tebaldi, Matteo, Andò, Giuseppe, Rigattieri, Stefano, Misuraca, Leonardo, Cortese, Bernardo, Musuraca, Gerardo, Lucci, Valerio, Guiducci, Vincenzo, Renda, Giulia, Zezza, Luigi, Versaci, Francesco, and Giannico, Maria Benedetta

Published
2024
Full Text
View/download PDF

15. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.

Author

Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, and Bari, Alessia

Subjects
CLINICAL trials, FOLLICULAR lymphoma, POSITRON emission tomography, OVERALL survival, PROGRESSION-free survival
Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1–3a FL/ stage II‐IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post‐induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1–3 was considered negative (CMR), whereas DS4‐5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients—52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3–5)—were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4–5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%–70%). The 5-yr PFS rate for PET neg (DS1–3) and PET pos (DS4–5) patients was 71% (95%CI: 67%–75%) and 36% (95%CI: 25%–46%), respectively, with HR 3.49 (95%CI: 2.57–4.72). Five-year PFS was worse as DS increased, with 74% (70%–78%), 58% (48%–67%; HR 1.71; p = 0.001)] and 36% (25%–46%; HR 3.88; p < 0.001) in DS1–2, DS3 and DS4–5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%–96%), with 96% (95%CI: 94–97) and 82% (95%CI: 72%–89%) in EOI PET negative (DS1–3) and positive (DS4–5), respectively (HR 4.48; p < 0.001). When DS was associated with FLIPI-2, patients with DS3 or DS1–2 with high FLIPI-2 (3–5) experienced worse OS than patients with DS1–2 and low FLIPI-2 (1–2) (p = 0.003). Conclusion: This study shows that DS is a reliable prognostic tool to evaluate EOI PET in follicular lymphoma patients, with prognostic value maintained both in the standard and experimental arms, making metabolic imaging a robust tool to assess response in FL. Moreover, although preliminary, this study provides further information on DS3 patients, who are considered as CMR but show a less favourable PFS than DS1–2 patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study

Author

Mauro, Francesca Romana, primary, Scalzulli, Potito Rosario, additional, Scarfò, Lydia, additional, Minoia, Carla, additional, Murru, Roberta, additional, Sportoletti, Paolo, additional, Frigeri, Ferdinando, additional, Albano, Francesco, additional, Di Renzo, Nicola, additional, Sanna, Alessandro, additional, Laurenti, Luca, additional, Massaia, Massimo, additional, Cassin, Ramona, additional, Coscia, Marta, additional, Patti, Caterina, additional, Pennese, Elsa, additional, Tafuri, Agostino, additional, Chiarenza, Annalisa, additional, Galieni, Piero, additional, Perbellini, Omar, additional, Selleri, Carmine, additional, Califano, Catello, additional, Ferrara, Felicetto, additional, Cuneo, Antonio, additional, Murineddu, Marco, additional, Palumbo, Gaetano, additional, Scortechini, Ilaria, additional, Tedeschi, Alessandra, additional, Trentin, Livio, additional, Varettoni, Marzia, additional, Pane, Fabrizio, additional, Liberati, Anna Marina, additional, Merli, Francesco, additional, Morello, Lucia, additional, Musuraca, Gerardo, additional, Tani, Monica, additional, Ibatici, Adalberto, additional, Regazzoni, Giulia, additional, Di Candia, Michele, additional, Palma, Maria, additional, Arienti, Danilo, additional, and Molica, Stefano, additional

Published
2024
Full Text
View/download PDF

17. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

Author

Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, Luminari, Stefano, Guerra, L, Chauvie, S, Fallanca, F, Bergesio, F, Marcheselli, L, Durmo, R, Peano, S, Franceschetto, A, Monaco, L, Barbieri, E, Ladetto, M, Musuraca, G, Tosi, P, Bianchi, B, Bolis, S, Pavone, V, Chiarenza, A, Arcari, A, Califano, C, Bari, A, Massaia, M, Conconi, A, Musto, P, Mannina, D, Roti, G, Galimberti, S, Gini, G, Falcinelli, F, Vitolo, U, Usai, S, Stefani, P, Ibatici, A, Liberati, A, Pennese, E, Perrone, T, Versari, A, Luminari, S, Guerra, Luca, Chauvie, Stephane, Fallanca, Federico, Bergesio, Fabrizio, Marcheselli, Luigi, Durmo, Rexhep, Peano, Simona, Franceschetto, Antonella, Monaco, Lavinia, Barbieri, Emiliano, Ladetto, Marco, Musuraca, Gerardo, Tosi, Patrizia, Bianchi, Benedetta, Bolis, Silvia Anna Maria, Pavone, Vincenzo, Chiarenza, Annalisa, Arcari, Annalisa, Califano, Catello, Bari, Alessia, Massaia, Massimo, Conconi, Annarita, Musto, Pellegrino, Mannina, Donato, Roti, Giovanni, Galimberti, Sara, Gini, Guido, Falcinelli, Flavio, Vitolo, Umberto, Usai, Sara Veronica, Stefani, Piero Maria, Ibatici, Adalberto, Liberati, Anna Marina, Pennese, Elsa, Perrone, Tommasina, Versari, Annibale, and Luminari, Stefano

Abstract

Purpose: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. Methods: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1-3 was considered negative (CMR), whereas DS4-5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). Results: Overall, 807 follicular lymphoma patients-52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3-5)-were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4-5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%-70%). The 5-yr PFS rate for PET neg (DS1-3) and PET pos (DS4-5) patients was 71% (95%CI: 67%-75%) and 36% (95%CI: 25%-46%), respectively, with HR 3.49 (95%CI: 2.57-4.72). Five-year PFS was worse as DS increased, with 74% (70%-78%), 58% (48%-67%; HR 1.71; p = 0.001)] and 36% (25%-46%; HR 3.88; p < 0.001) in DS1-2, DS3 and DS4-5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%-96%), with 96% (95%CI: 94-97

Published
2024

18. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Author

Zelenetz, Andrew D., Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collins, Graham P., Jiménez, Javier L., Bishton, Mark, Dholaria, Bhagirathbhai, Mengarelli, Andrea, Phillips, Tycel J., Sungala, Nagendraprasad, Musuraca, Gerardo, Sheehy, Oonagh, Van Den Neste, Eric, Odera, Mitsuhiko, Miao, Lu, Gold, Daniel P., Ghalie, Richard G., and Zinzani, Pier L.

Published
2024
Full Text
View/download PDF

20. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

Author

Stathis, Anastasios, primary, Pirosa, Maria Cristina, additional, Orsucci, Lorella, additional, Feugier, Pierre, additional, Tani, Monica, additional, Ghesquières, Hervé, additional, Musuraca, Gerardo, additional, Rossi, Francesca Gaia, additional, Merli, Francesco, additional, Guièze, Romain, additional, Gyan, Emmanuel, additional, Gini, Guido, additional, Marino, Dario, additional, Gressin, Remy, additional, Morschhauser, Franck, additional, Cavallo, Federica, additional, Palombi, Francesca, additional, Conconi, Annarita, additional, Tessoulin, Benoît, additional, Tilly, Hervé, additional, Zanni, Manuela, additional, Cabras, Maria Giuseppina, additional, Capochiani, Enrico, additional, Califano, Catello, additional, Celli, Melania, additional, Pulsoni, Alessandro, additional, Angrilli, Francesco, additional, Occhini, Ubaldo, additional, Casasnovas, René-Olivier, additional, Cartron, Guillaume, additional, Devizzi, Liliana, additional, Haioun, Corinne, additional, Liberati, Anna Marina, additional, Houot, Roch, additional, Merli, Michele, additional, Pietrantuono, Giuseppe, additional, Re, Francesca, additional, Spina, Michele, additional, Landi, Francesco, additional, Cavalli, Franco, additional, Bertoni, Francesco, additional, Rossi, Davide, additional, Ielmini, Nicoletta, additional, Borgo, Elena, additional, Luminari, Stefano, additional, Zucca, Emanuele, additional, and Thieblemont, Catherine, additional

Published
2024
Full Text
View/download PDF

21. Local Radiotherapy and MRD-Driven Immunotherapy in Early-Stage Follicular Lymphoma: Final Results of the FIL - 'MIRO' Multicenter Phase II Trial

Author

Pulsoni, Alessandro, primary, Ferrero, Simone, additional, Tosti, Maria Elena, additional, Luminari, Stefano, additional, Dondi, Alessandra, additional, Cavallo, Federica, additional, Merli, Francesco, additional, Liberati, Anna Marina, additional, Cenfra, Natalia, additional, Renzi, Daniela, additional, Zanni, Manuela, additional, Boccomini, Carola, additional, Ferreri, Andrés, additional, Rattotti, Sara, additional, Zilioli, Vittorio Ruggero, additional, Bolis, Silvia Anna, additional, Bernuzzi, Patrizia, additional, Musuraca, Gerardo, additional, Gaidano, Gianluca, additional, Perrone, Tommasina, additional, Stelitano, Caterina, additional, Tucci, Alessandra, additional, Corradini, Paolo, additional, Bigliardi, Sara, additional, Re, Francesca, additional, Cencini, Emanuele, additional, Mannarella, Clara, additional, Mannina, Donato, additional, Celli, Melania, additional, Tani, Monica, additional, Annechini, Giorgia, additional, Assanto, Giovanni Manfredi, additional, Grapulin, Lavinia, additional, Guarini, Anna, additional, Cavalli, Marzia, additional, De Novi, Lucia Anna, additional, Bomben, Riccardo, additional, Ciabatti, Elena, additional, Genuardi, Elisa, additional, Drandi, Daniela, additional, Della Starza, Irene, additional, Arcaini, Luca, additional, Ricardi, Umberto, additional, Gattei, Valter, additional, Galimberti, Sara, additional, Ladetto, Marco, additional, Foà, Robin, additional, and del Giudice, Ilaria, additional

Published
2024
Full Text
View/download PDF

22. Correction: Bocci et al. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma. J. Clin. Med. 2022, 11, 7162

Author

Bocci, Guido, primary, Pelliccia, Sabrina, additional, Orlandi, Paola, additional, Caridi, Matteo, additional, Banchi, Marta, additional, Musuraca, Gerardo, additional, Di Napoli, Arianna, additional, Bianchi, Maria Paola, additional, Patti, Caterina, additional, Anticoli-Borza, Paola, additional, Battistini, Roberta, additional, Casaroli, Ivana, additional, Lanzolla, Tiziana, additional, Tafuri, Agostino, additional, and Cox, Maria Christina, additional

Published
2023
Full Text
View/download PDF

23. P-057 Role of the combination of FDG-PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: a prospective trial

Author

Cerchione, Claudio, primary, Nappi, Davide, additional, Marchesini, Matteo, additional, Ronconi, Sonia, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Rossi, Alice, additional

Published
2023
Full Text
View/download PDF

26. POSTER: MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial

Author

Cerchione, Claudio, primary, Nappi, Davide, additional, Marchesini, Matteo, additional, Feliciani, Giacomo, additional, Iamurri, Andrea Prochowski, additional, Ronconi, Sonia, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Matuozzo, Claudia, additional, Mammoli, Fabiana, additional, Frabetti, Federica, additional, Paganelli, Giovanni, additional, Matteucci, Federica, additional, Pallotti, Caterina, additional, Scarpi, Emanuela, additional, Pazzi, Chiara, additional, Barone, Domenico, additional, Romeo, Antonino, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Rossi, Alice, additional

Published
2023
Full Text
View/download PDF

28. MM-602 Role of the Combination of FDG-PET Plus Whole Body MRI for Staging Patients With High-Risk Smoldering Myeloma: A Prospective Trial

Author

Cerchione, Claudio, primary, Nappi, Davide, additional, Marchesini, Matteo, additional, Feliciani, Giacomo, additional, Iamurri, Andrea Prochowski, additional, Ronconi, Sonia, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Matuozzo, Claudia, additional, Mammoli, Fabiana, additional, Frabetti, Federica, additional, Paganelli, Giovanni, additional, Matteucci, Federica, additional, Pallotti, Caterina, additional, Scarpi, Emanuela, additional, Pazzi, Chiara, additional, Barone, Domenico, additional, Romeo, Antonino, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Rossi, Alice, additional

Published
2023
Full Text
View/download PDF

33. IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study

Author

Phillips, Tycel, Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collin, Graham P., Lopéz-Jimenéz, Javier, Reddy, Nishitha, Mengarelli, Andrea, Musuraca, Gerardo, Sheehy, Oonagh, Xu, Weiming, Azoulay, Michel, Ghalie, Richard G., Zinzani, Pier Luigi, and Zelenetz, Andrew D.

Published
2022
Full Text
View/download PDF

36. PB1792: REPURPOSING OF ANTIBIOTICS INHIBITING MITOCHONDRIAL TRANSLATION IN COMBINATION WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA: FROM PRECLINICAL MODELS TO CLINICAL PRACTICE

Author

Amato, Viviana, primary, Fusani, Stefania, additional, Papayannidis, Cristina, additional, Nanni, Jacopo, additional, Curti, Antonio, additional, Marchesi, Francesco, additional, Fanciulli, Maurizio, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Marconi, Giovanni, additional, Gottardi, Michele, additional, Sperotto, Alessandra, additional, Rossi, Alessandra, additional, Maraglino, Alessio Maria Edoardo, additional, Sammassimo, Simona, additional, Gigli, Federica, additional, Todisco, Elisabetta, additional, Tarella, Corrado, additional, Giglio, Fabio, additional, and Derenzini, Enrico, additional

Published
2023
Full Text
View/download PDF

37. P953: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING NEWLY DIAGNOSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PROSPECTIVE TRIAL

Author

Cerchione, Claudio, primary, Nappi, Davide, additional, Marchesini, Matteo, additional, Feliciani, Giacomo, additional, Prochowski Iamurri, Andrea, additional, Ronconi, Sonia, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Matuozzo, Claudia, additional, Mammoli, Fabiana, additional, Frabetti, Federica, additional, Paganelli, Giovanni, additional, Matteucci, Federica, additional, Pallotti, Caterina, additional, Scarpi, Emanuela, additional, Pazzi, Chiara, additional, Barone, Domenico, additional, Romeo, Antonino, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Rossi, Alice, additional

Published
2023
Full Text
View/download PDF

39. P918: ROLE OF THE COMBINATION OF FDG PET PLUS WHOLE BODY MRI FOR STAGING PATIENTS IN HIGH RISK SMOLDERING MYELOMA: A PROSPECTIVE TRIAL

Author

Cerchione, Claudio, primary, Nappi, Davide, additional, Marchesini, Matteo, additional, Ronconi, Sonia, additional, Cangini, Delia, additional, Ceccolini, Michela, additional, Feliciani, Giacomo, additional, Prochowski Iamurri, Andrea, additional, Matuozzo, Claudia, additional, Mammoli, Fabiana, additional, Frabetti, Federica, additional, Paganelli, Giovanni, additional, Matteucci, Federica, additional, Pallotti, Caterina, additional, Scarpi, Emanuela, additional, Pazzi, Chiara, additional, Barone, Domenico, additional, Romeo, Antonino, additional, Simonetti, Giorgia, additional, Musuraca, Gerardo, additional, Martinelli, Giovanni, additional, and Rossi, Alice, additional

Published
2023
Full Text
View/download PDF

42. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

Author

Nizzoli, Maria E., primary, Manni, Martina, additional, Ghiggi, Chiara, additional, Pulsoni, Alessandro, additional, Musuraca, Gerardo, additional, Merli, Michele, additional, Califano, Catello, additional, Bari, Alessia, additional, Massaia, Massimo, additional, Conconi, Annarita, additional, Musto, Pellegrino, additional, Mannina, Donato, additional, Perrone, Tommasina, additional, Re, Francesca, additional, Galimberti, Sara, additional, Gini, Guido, additional, Capponi, Monia, additional, Vitolo, Umberto, additional, Usai, Sara V., additional, Stefani, Piero M., additional, Ballerini, Filippo, additional, Liberati, Anna M., additional, Pennese, Elsa, additional, Pastore, Domenico, additional, Skrypets, Tetiana, additional, Catellani, Hillary, additional, Marcheselli, Luigi, additional, Federico, Massimo, additional, and Luminari, Stefano, additional

Published
2023
Full Text
View/download PDF

43. High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC1518 - 'Veritas' study

Author

Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, Laurenti, Luca (ORCID:0000-0002-8327-1396), Mauro, Francesca R, Starza, Irene Della, Messina, Monica, Reda, Gianluigi, Trentin, Livio, Coscia, Marta, Sportoletti, Paolo, Orsucci, Lorella, Arena, Valentina, Casaluci, Gloria Margiotta, Marasca, Roberto, Murru, Roberta, Laurenti, Luca, Ilariucci, Fiorella, Stelitano, Caterina, Mannina, Donato, Massaia, Massimo, Rigolin, Gian Matteo, Scarfò, Lydia, Marchetti, Monia, Levato, Luciano, Tani, Monica, Arcari, Annalisa, Musuraca, Gerardo, Deodato, Marina, Galieni, Piero, Patrizi, Valeria Belsito, Gottardi, Daniela, Liberati, Anna Marina, Giordano, Annamaria, Molinari, Maria Chiara, Pietrasanta, Daniela, Mattiello, Veronica, Visentin, Andrea, Vitale, Candida, Albano, Francesco, Neri, Antonino, De Novi, Lucia Anna, De Propris, Maria Stefania, Nanni, Mauro, Del Giudice, Ilaria, Guarini, Anna, Fazi, Paola, Vignetti, Marco, Piciocchi, Alfonso, Cuneo, Antonio, Foà, Robin, and Laurenti, Luca (ORCID:0000-0002-8327-1396)

Abstract

The GIMEMA phase II LLC1518 VERITAS trial investigated the efficacy and safety of frontline, fixed-duration venetoclax and rituximab (VenR) combination in young (≤65 years) and fit patients with chronic lymphocytic leukemia (CLL) and unmutated IGHV and/or TP53 disruption. Treatment consisted of the Ven ramp-up, six-monthly courses of the VenR combination, followed by six monthly courses of Ven single agent. A centralized assessment of measurable minimal residual disease (MRD) was performed on the peripheral blood (PB) and bone marrow (BM) by ASO-PCR at the end of treatment (EOT) and during the follow-up. The primary endpoint was the complete remission (CR) rate at the EOT. Seventy-five patients were enrolled; the median age was 54 years (range 38-65), 96% had unmutated IGHV, 9 (12%) had TP53 disruption, and 4% were IGHV mutated with TP53 disruption. The overall response rate (ORR) at the EOT was 94.7%, with a CR rate of 76%. An undetectable (u) MRD was recorded in 69.3% of patients in the PB and 58.7% in the BM. The 12-month MRD-free survival in the 52 patients with uMRD in the PB at the EOT was 73.1%. After a median follow-up of 20.8 months, no disease progressions were observed. Three patients have died, two due to Covid-19 and 1 to tumor lysis syndrome. The first report of the VERITAS study shows that frontline VenR was associated with a high rate of CRs and durable responses with uMRD in young patients with CLL and unfavorable genetic characteristics.

Published
2023

45. High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

Author

Mauro, Francesca R., primary, Starza, Irene Della, additional, Messina, Monica, additional, Reda, Gianluigi, additional, Trentin, Livio, additional, Coscia, Marta, additional, Sportoletti, Paolo, additional, Orsucci, Lorella, additional, Arena, Valentina, additional, Casaluci, Gloria Margiotta, additional, Marasca, Roberto, additional, Murru, Roberta, additional, Laurenti, Luca, additional, Ilariucci, Fiorella, additional, Stelitano, Caterina, additional, Mannina, Donato, additional, Massaia, Massimo, additional, Rigolin, Gian Matteo, additional, Scarfò, Lydia, additional, Marchetti, Monia, additional, Levato, Luciano, additional, Tani, Monica, additional, Arcari, Annalisa, additional, Musuraca, Gerardo, additional, Deodato, Marina, additional, Galieni, Piero, additional, Patrizi, Valeria Belsito, additional, Gottardi, Daniela, additional, Liberati, Anna Marina, additional, Giordano, Annamaria, additional, Molinari, Maria Chiara, additional, Pietrasanta, Daniela, additional, Mattiello, Veronica, additional, Visentin, Andrea, additional, Vitale, Candida, additional, Albano, Francesco, additional, Neri, Antonino, additional, De Novi, Lucia Anna, additional, De Propris, Maria Stefania, additional, Nanni, Mauro, additional, Del Giudice, Ilaria, additional, Guarini, Anna, additional, Fazi, Paola, additional, Vignetti, Marco, additional, Piciocchi, Alfonso, additional, Cuneo, Antonio, additional, and Foà, Robin, additional

Published
2023
Full Text
View/download PDF

46. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly and Frail Patients, with Diffuse Large B-Cell Lymphoma

Author

Bocci, Guido, primary, Pelliccia, Sabrina, additional, Orlandi, Paola, additional, Caridi, Matteo, additional, Banchi, Marta, additional, Musuraca, Gerardo, additional, Di Napoli, Arianna, additional, Bianchi, Maria Paola, additional, Patti, Caterina, additional, Anticoli-Borza, Paola, additional, Battistini, Roberta, additional, Casaroli, Ivana, additional, Lanzolla, Tiziana, additional, Tafuri, Agostino, additional, and Cox, Maria Christina, additional

Published
2022
Full Text
View/download PDF

47. Diffuse large B-cell lymphoma in octogenarians aged 85 and older can benefit from treatment with curative intent: a report on 129 patients prospectively registered in the Elderly Project of the Fondazione Italiana Linfomi (FIL)

Author

Tucci, Alessandra, primary, Merli, Francesco, additional, Fabbri, Alberto, additional, Marcheselli, Luigi, additional, Pagani, Chiara, additional, Puccini, Benedetta, additional, Marino, Dario, additional, Zanni, Manuela, additional, Pennese, Elsa, additional, Flenghi, Leonardo, additional, Arcari, Annalisa, additional, Botto, Barbara, additional, Celli, Melania, additional, Mammi, Caterina, additional, Re, Alessandro, additional, Campostrini, Giulia, additional, Tafuri, Agostino, additional, Zilioli, Vittorio R., additional, Cencini, Emanuele, additional, Sartori, Roberto, additional, Bottelli, Chiara, additional, Merli, Michele, additional, Petrucci, Luigi, additional, Gini, Guido, additional, Balzarotti, Monica, additional, Cavallo, Federica, additional, Musuraca, Gerardo, additional, Luminari, Stefano, additional, Rossi, Giuseppe, additional, and Spina, Michele, additional

Published
2022
Full Text
View/download PDF

48. Total Metabolic Tumor Volume Is Confirmed As Independent Prognostic Factor in Treatment Naïve Follicular Lymphoma Patients and Can be Combined with FLIPI2 to Improve Prognostic Accuracy. a FOLL12 Substudy By the Fondazione Italiana Linfomi

Author

Luminari, Stefano, primary, Guerra, Luca, additional, Minoia, Carla, additional, Chauvie, Stephane, additional, Anastasia, Antonella, additional, Cavallo, Federica, additional, Corradini, Paolo, additional, Rattotti, Sara, additional, Durmo, Rexhep, additional, Ghiggi, Chiara, additional, Olivieri, Jacopo, additional, Ferrero, Simone, additional, Margiotta Casaluci, Gloria, additional, Nassi, Luca, additional, Stelitano, Caterina, additional, Ricci, Francesca, additional, Zilioli, Vittorio Ruggero, additional, Pinto, Antonio, additional, Zanni, Manuela, additional, Silvia, Bolis, additional, Patti, Caterina, additional, Merli, Michele, additional, Chiarenza, Annalisa, additional, Musuraca, Gerardo, additional, Tosi, Patrizia, additional, Federico, Massimo, additional, and Versari, Annibale, additional

Published
2022
Full Text
View/download PDF

50. Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

Author

Cox, M. Christina, primary, Pelliccia, Sabrina, additional, Orlandi, Paola, additional, Di Napoli, Arianna, additional, Musuraca, Gerardo, additional, Patti, Caterina, additional, Bianchi, Maria Paola, additional, Caridi, Matteo, additional, Banchi, Marta, additional, Battistini, Roberta, additional, Lanzolla, Tiziana, additional, Tafuri, Agostino, additional, and Bocci, Guido, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results